Search details
1.
Real-world evidence of multiple myeloma treated from 2013 to 2019 in the Hospital District of Helsinki and Uusimaa, Finland.
Future Oncol
; 19(30): 2029-2043, 2023 Sep.
Article
in English
| MEDLINE | ID: mdl-37828901
2.
Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland.
Acta Derm Venereol
; 102: adv00693, 2022 Apr 08.
Article
in English
| MEDLINE | ID: mdl-35356995
3.
Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.
Mol Ther
; 24(1): 175-83, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-26310629
4.
Synergistic anti-tumor efficacy of immunogenic adenovirus ONCOS-102 (Ad5/3-D24-GM-CSF) and standard of care chemotherapy in preclinical mesothelioma model.
Int J Cancer
; 139(8): 1883-93, 2016 10 15.
Article
in English
| MEDLINE | ID: mdl-27287512
5.
Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
Mol Ther
; 23(10): 1641-52, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26156245
6.
Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma.
Int J Cancer
; 136(4): 945-54, 2015 Feb 15.
Article
in English
| MEDLINE | ID: mdl-24975392
7.
Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
Int J Cancer
; 137(7): 1775-83, 2015 Oct 01.
Article
in English
| MEDLINE | ID: mdl-25821063
8.
Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Int J Cancer
; 135(3): 720-30, 2014 Aug 01.
Article
in English
| MEDLINE | ID: mdl-24374597
9.
Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 - Support for clinical studies on advanced cancer treatment.
PLoS One
; 12(8): e0182715, 2017.
Article
in English
| MEDLINE | ID: mdl-28796812
10.
Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.
Oncoimmunology
; 6(2): e1265717, 2017.
Article
in English
| MEDLINE | ID: mdl-28344872
11.
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.
Oncoimmunology
; 5(2): e1078057, 2016 Feb.
Article
in English
| MEDLINE | ID: mdl-27057453
12.
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers.
J Immunother Cancer
; 4: 17, 2016.
Article
in English
| MEDLINE | ID: mdl-26981247
13.
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+ T-cell response, prominent infiltration of CD8+ lymphocytes and Th1 type polarization.
Oncoimmunology
; 3(10): e958937, 2014 Nov.
Article
in English
| MEDLINE | ID: mdl-25941579
Results
1 -
13
de 13
1
Next >
>>